Selena Ferrian,Aiqin Cao,Erin McCaffrey,Toshie Saito,Noah F. Greenwald,Mark R. Nicolls,Trevor Bruce,Roham T. Zamanian,Patricia Del Rosario,Marlene Rabinovitch,Michael Angelo
Unraveling immune-driven vascular pathology in pulmonary arterial hypertension (PAH) requires a comprehensive understanding of the immune cell landscape. Although patients with hereditary (H)PAH and bone morphogenetic protein receptor type 2 (BMPR2) mutations have more severe pulmonary vascular pathology, it is not known whether this is related to specific immune cell subsets.